Paradigm-Changing Triplet Therapy for MesotheliomaParadigm-Changing Triplet Therapy for Mesothelioma

Bevacizumab added to standard of care provided significantly longer overall survival for patients with malignant pleural mesothelioma. Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Related Links:

Publication date: Available online 12 October 2019Source: Annals of Medicine and SurgeryAuthor(s): Clement Brun, Sophie Giusiano, Khady Thiam, Julien Guinde, Marios Froudarakis, Philippe AstoulAbstractMesothelioma of the tunica vaginalis of the testis (MTVM) is a rare tumor encountering for less than 1% of mesothelioma. Patients suffering from these tumors have poor survival due to local and distant metastasis despite treatment. Actually, no specific treatment recommendations exist for this tumor, yet radical orchidectomy is the gold standard in limited disease. We herein report the case of a 71 patient with MTVM who under...
Source: Annals of Medicine and Surgery - Category: General Medicine Source Type: research
Conclusion: This is the first description of gC1qR expression in MPM. The data identify gC1qR as a potential new prognostic factor in patients treated with surgery and chemotherapy.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
This study aimed to investigate the feasibility of fitting dual-input tracer kinetic models to DCE-MRI datasets of thoracic malignancies, including malignant pleural mesothelioma (MPM) and nonsmall cell lung cancer (NSCLC), by comparing them to single-input (pulmonary or systemic arterial input) tracer kinetic models for the voxel-level analysis within the tumor with respect to goodness-of-fit statistics. Fifteen patients (five MPM, ten NSCLC) underwent DCE-MRI prior to radiotherapy. DCE-MRI data were analyzed using five different single- or dual-input tracer kinetic models: Tofts-Kety (TK), extended TK (ETK), two compartm...
Source: Journal of Applied Clinical Medical Physics - Category: Physics Authors: Tags: J Appl Clin Med Phys Source Type: research
Authors: Kuribayashi K, Doi H, Kijima T Abstract Introduction: The surgical arm of the Mesothelioma and Radical Surgery (MARS) trial involved a multimodal approach, with combined therapy consisting of chemotherapy, complete gross resection, and radiation therapy. However, the MARS trial did not compare surgery with chemotherapy, and the survival and quality of life outcomes of this trial's surgical arm were inferior to those of the non-surgical arm. Methods for achieving complete gross resection (macroscopic complete response [MCR]) include extrapleural pneumonectomy (EPP), wherein the pleura, lung, diaphragm, and ...
Source: Expert Review of Respiratory Medicine - Category: Respiratory Medicine Tags: Expert Rev Respir Med Source Type: research
Authors: Ceresoli GL, Rossi A Abstract Introduction: Malignant pleural mesothelioma (MPM) is a rare neoplasm with asbestos exposure as the dominant etiologic agent. Owing to the long latent period following exposure, MPM is often diagnosed late in life. Despite this, elderly patients are under-represented in clinical trials. To date, data regarding the tolerability and efficacy of anticancer treatments for elderly patients affected by MPM are still lacking. Areas covered: The current state-of-the-art of approved treatments employed in the treatment MPM elderly patients is reviewed and discussed, with a look to emer...
Source: Expert Review of Respiratory Medicine - Category: Respiratory Medicine Tags: Expert Rev Respir Med Source Type: research
The contribution of the complement system in the pathophysiology of brain cancers has been recently considered in light of its well-known involvement in carcinogenesis. Complement system represents an important component of the inflammatory response, which acts as a functional bridge between the innate and adaptive immune response. C1q, the first recognition subcomponent of the complement classical pathway, has recently been shown to be involved in a range of pathophysiological functions that are not dependent on complement activation. C1q is expressed in the microenvironment of various types of human tumors, including mel...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Glaring safety issues involving asbestos exposure within the Metropolitan Transportation Authority extend further than the East New York bus depot in Brooklyn, a report from the agency’s inspector general alleges. Inhaling or ingesting tiny asbestos fibers in the air can lead to serious health conditions later in life, including mesothelioma cancer. The inspector general report, released Monday, shows MTA managers ignored asbestos safety concerns at bus and train facilities across New York City for years. Asbestos-containing materials were found in disrepair in the boiler rooms of at least six MTA depots throughout...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Kocher Schmid Peng Malignant pleural mesothelioma (MPM) is a lethal cancer with limited treatment options. No targeted therapy has emerged yet. Here, we performed an integrated molecular characterization of patient tumors in the TCGA dataset, and discovered that endoplasmic reticulum (ER) stress and the adaptive unfolded protein response (UPR) signaling are characteristically deregulated in MPM. Consequently, pharmacological perturbation of ER stress/UPR axis by HA15, an agent that induces persistent proteotoxic stress in the ER, selectively suppresses the viability of MPM cells including those refractory to stan...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Results from a phase III clinical trial comparing Keytruda (pembrolizumab) to standard chemotherapy shows the immunotherapy drug still has a long way to go as a viable treatment option for malignant pleural mesothelioma. Keytruda did not improve progression-free survival for mesothelioma patients who progressed after first-line chemotherapy. The disappointing results from the PROMISE-meso study were presented at the European Society of Medical Oncology (ESMO) annual meeting last week. It was the first randomized trial comparing progression-free survival between immunotherapy and first-line chemotherapy for mesothelioma p...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Condition:   Pleura Mesothelioma Intervention:   Drug: Durvalumab Sponsor:   Mario Negri Institute for Pharmacological Research Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Asbestosis | Avastin | Cancer & Oncology | Hematology | Mesothelioma